{"entity":{"id":"m3t01","kind":"drug","name":"M3T01","aka":[],"tldr":"M3T01 is an antibody from Gamma Biotherapeutics that blocks Fas ligand to protect cancer-fighting T cells, in a phase 1 trial in advanced solid tumours.","summary":"M3T01 is the lead programme of Gamma Biotherapeutics, a monoclonal antibody against Fas ligand. It is being tested as monotherapy and with pembrolizumab and other systemic therapies in a phase 1 trial in advanced solid tumours, NCT06719362, sponsored by Providence Health & Services and recruiting since June 2025. The National Cancer Institute funds its clinical development through an SBIR award (1R44CA310416-01).","status":"phase-1","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov: NCT06719362","url":"https://clinicaltrials.gov/study/NCT06719362"},{"label":"NIH RePORTER: 1R44CA310416-01","url":"https://reporter.nih.gov/project-details/11315901"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gamma-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"M3T01","modality":"Monoclonal antibody","mechanism":"Neutralises Fas ligand (FasL), which tumours produce and which drives apoptosis of activated T cells, so that T cells survive to enter and attack the tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/m3t01/","neighbours":{"company":[{"id":"gamma-biotherapeutics","kind":"company","name":"Gamma Biotherapeutics","route":"/companies/gamma-biotherapeutics/"}]}}